Linfeng Yang

Targeting circGDI2 disrupt HNRNPC-mediated mPORCN stabilization and enhance LGK-974 anti-tumor therapy in hepatocellular carcinoma

Yang Huang, Liangliang Xu, Linfeng Yang, Zhenru Wu et autres

BACKGROUND: The functions of circRNAs in hepatocellular carcinoma (HCC) till needs to be further elucidated. METHODS: We assessed the biological functions of circGDI2 in vitro and in vivo by gain or loss of function experiments. Then, fuorescence in situ hybridization (FISH), immunofluorescence …

cn, hk (code pays fourni par la source)

Targeting circGDI2 disrupt HNRNPC-mediated mPORCN stabilization and enhance LGK-974 anti-tumor therapy in hepatocellular carcinoma

Yang Huang, Liangliang Xu, Linfeng Yang, Zhenru Wu et autres

cn, hk (code pays fourni par la source)

Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis

Yong Li, Xingyu Liu, Junning Liu, Linfeng Yang et autres

The use of tyrosine kinase inhibitors combined with transarterial chemoembolization (TACE) is considered the standard therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, information regarding the efficacy of lenvatinib or sorafenib in combination with TACE for patients with uHCC is limited. …

cn (code pays fourni par la source)